How Genetics is Being Used to Drive Drug Discovery & Development

Wednesday March 31, 2021 8:00am PST | 11:00am EST

Engager hosted by Genomenon

Genomenon Logo 2021 - stacked tag-28 (new)

The March Genomenon Engager will cover:

How Genetics is Being Used to Drive Drug Discovery & Development

Welcome to the Genomenon Engager, an exclusive event providing leaders in pharma and biotech with opportunities to explore the deep and invaluable connection between drug development and genomics and learn how advances in genomics can equip biopharma with new capabilities that expedite their regulatory approval journey.

With 90% of IND applications currently failing approval processes and leading to repeated R&D failures in the lab, diminished likelihood of success in clinical trials, and/or inappropriate diagnosis and treatment of patients in the clinic, join this Engager to benchmark against the current state of genomic research and drug development. Don't miss out on your chance to discover how you can improve your genomic strategy to establish more efficacious clinical trials and increase the chance of FDA approval with genetic evidence support.

KEY OBJECTIVES

  • Learn how to choose a better starting point for therapies while reducing R&D costs by focusing on validating targets
  • Explore the deep and invaluable connection between drug development and genomics and how they are driving innovation with genomic knowledge within pharma
  • Increase success of clinical trials through optimized patient selection and decreasing time to market

 

Following a Q&A, attendees can connect with key Genomenon executives and members to converse and dig a bit deeper into the topics covered throughout the session.

EXPERT SPEAKERS

Alastair Garfield

VP, Head of Translational Research

Rhythm Phamaceuticals

Heiko Runz

Medical Director Genetics

Biogen

Mark Kiel

Chief Science Officer

Genomenon

Tom Defay

Deputy Head Diagnostics Strategy & Development

Alexion Pharmaceuticals

WHO SHOULD ATTEND

This is an exclusive event for Directors, Heads and VPs of Data Science, R&D, Translation & Diagnostics in Neurodegenerative Diseases looking to get an overview of how advances in genomics equip both pharma and biopharma with new capabilities that accelerate their regulatory approval journey and increases clinical trials success.

This digital event will bring different perspectives from precision medicine executives to help understand the current state of genomic research and drug discovery and how to increase success of clinical trials through optimized patient selection and decreasing time to market.

ABOUT GENOMENON

Genomenon Logo 2021 - stacked tag-28 (new)

Genomenon’s AI-driven genomic engine leverages billions of genetic associations between diseases, phenotypes and therapies found across the medical research. They deliver a comprehensive genomic landscape for every disease, including rare, neurodegenerative, and genetic diseases, as well as somatic and germline cancer.

Armed with a comprehensive base of molecular biomarkers and disease mechanisms, Genomenon’s customers expand their genetic knowledge of the disease drivers by a factor of 10-20X to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval.